A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). Dumbrava, E., Dougan, M. L., Gupta, S., Cappelli, L., Katsumoto, T. R., Rahma, O. E., Painter, J., Wang, Y., Suarez-Almazor, M. E., Reid, P., Wesley, S. F., Hafler, D. A., Bingham, C. O., Warner, B. M., Chung, L., Ott, P., Kluger, H. M., Khosroshahi, A., Tawbi, H., Sharon, E. LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for DOI 10.1200/JCO.2021.39.15_suppl.TPS2676

View details for Web of Science ID 000708120306215